Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
finance.yahoo.com
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels,...
Shares of Biocept Inc. BIOC, 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares. the company said in a statement. The...
*****WE KEEP ALERTS SET ON THIS NAME AND BUY ORDER IN PLACE, RUMOR HAS IT THERE IS A MOVE COMING SOON, WITH MASSIVE UPSIDE POTENTIAL******
James mc Carthy from MAxim recently maintained his buy rating and initiated a $3 price target citing.
“Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the...
What I like about BIOC:
1. Higher lows on the daily
2. RSI crossed above the 50
3. MACD still bullish
4. Range to 50ma within reach.
5. Break above 50ma could fill gap to .49
6. MA's in alignment.
7. Showed up on EOD scan - 87% chance of running tomorrow.
The stock is a big % Gainer , it will be in the watchlist of many traders this week and might be going up after its apocalypse
The price now is in a rang between 1.80 and 1.40
If it will break The 1.80 , we have a great probability to go long to the 3.37 ( Last Big top ) forming perhaps a double top for another colapse ( Or not )
If it will break the 1.40 ,...
Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of...
The pennant consolidation is about over, it is ready to break out and make the next leg of its upward journey starting out with a measured move. Since it is so close to the apex of the pennant with a doji, anyone short should consider covering immediately.
Industry:Medical Equipment, Supplies & Distribution
Employees:42
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
BIOC
